Terms: = Prostate cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Clinical Outcome
12 results:
1. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
2. Use of Circulating Tumor DNA for the clinical Management of Metastatic Castration-Resistant prostate cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract] [Full Text] [Related]
3. Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.
Chow K; Bedő J; Ryan A; Agarwal D; Bolton D; Chan Y; Dundee P; Frydenberg M; Furrer MA; Goad J; Gyomber D; Hanegbi U; Harewood L; King D; Lamb AD; Lawrentschuk N; Liodakis P; Moon D; Murphy DG; Peters JS; Ruljancich P; Verrill CL; Webb D; Wong LM; Zargar H; Costello AJ; Papenfuss AT; Hovens CM; Corcoran NM
Eur J Cancer; 2021 May; 148():440-450. PubMed ID: 33678516
[TBL] [Abstract] [Full Text] [Related]
4. Genomic correlates of clinical outcome in advanced prostate cancer.
Abida W; Cyrta J; Heller G; Prandi D; Armenia J; Coleman I; Cieslik M; Benelli M; Robinson D; Van Allen EM; Sboner A; Fedrizzi T; Mosquera JM; Robinson BD; De Sarkar N; Kunju LP; Tomlins S; Wu YM; Nava Rodrigues D; Loda M; Gopalan A; Reuter VE; Pritchard CC; Mateo J; Bianchini D; Miranda S; Carreira S; Rescigno P; Filipenko J; Vinson J; Montgomery RB; Beltran H; Heath EI; Scher HI; Kantoff PW; Taplin ME; Schultz N; deBono JS; Demichelis F; Nelson PS; Rubin MA; Chinnaiyan AM; Sawyers CL
Proc Natl Acad Sci U S A; 2019 Jun; 116(23):11428-11436. PubMed ID: 31061129
[TBL] [Abstract] [Full Text] [Related]
5. The Evolutionary Landscape of Localized prostate cancers Drives clinical Aggression.
Espiritu SMG; Liu LY; Rubanova Y; Bhandari V; Holgersen EM; Szyca LM; Fox NS; Chua MLK; Yamaguchi TN; Heisler LE; Livingstone J; Wintersinger J; Yousif F; Lalonde E; Rouette A; Salcedo A; Houlahan KE; Li CH; Huang V; Fraser M; van der Kwast T; Morris QD; Bristow RG; Boutros PC
Cell; 2018 May; 173(4):1003-1013.e15. PubMed ID: 29681457
[TBL] [Abstract] [Full Text] [Related]
6. Differential impact of RB status on E2F1 reprogramming in human cancer.
McNair C; Xu K; Mandigo AC; Benelli M; Leiby B; Rodrigues D; Lindberg J; Gronberg H; Crespo M; De Laere B; Dirix L; Visakorpi T; Li F; Feng FY; de Bono J; Demichelis F; Rubin MA; Brown M; Knudsen KE
J Clin Invest; 2018 Jan; 128(1):341-358. PubMed ID: 29202480
[TBL] [Abstract] [Full Text] [Related]
7. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract] [Full Text] [Related]
8. The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells.
Libertini SJ; Chen H; al-Bataina B; Koilvaram T; George M; Gao AC; Mudryj M
Prostate; 2012 May; 72(6):649-60. PubMed ID: 21837779
[TBL] [Abstract] [Full Text] [Related]
9. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.
Sharma A; Yeow WS; Ertel A; Coleman I; Clegg N; Thangavel C; Morrissey C; Zhang X; Comstock CE; Witkiewicz AK; Gomella L; Knudsen ES; Nelson PS; Knudsen KE
J Clin Invest; 2010 Dec; 120(12):4478-92. PubMed ID: 21099110
[TBL] [Abstract] [Full Text] [Related]
10. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
[TBL] [Abstract] [Full Text] [Related]
11. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
Chakravarti A; Heydon K; Wu CL; Hammond E; Pollack A; Roach M; Wolkov H; Okunieff P; Cox J; Fontanesi J; Abrams R; Pilepich M; Shipley W;
J Clin Oncol; 2003 Sep; 21(17):3328-34. PubMed ID: 12947069
[TBL] [Abstract] [Full Text] [Related]
12. Tumour suppressor genes in prostate cancer.
MacGrogan D; Bookstein R
Semin Cancer Biol; 1997 Feb; 8(1):11-9. PubMed ID: 9299577
[TBL] [Abstract] [Full Text] [Related]
